We can’t show the full text here under this license.
Abstract
Adoptive cell immunotherapy using CARs specific for CD19 has shown remarkable responses in some patients with hematological malignancies.
- CAR-T cell therapy has limited clinical efficacy in treating solid tumors.
- Immunosuppression in solid tumors may arise from multiple mechanisms.
- Strategies to enhance T cell effectiveness in solid tumors are being explored.
- The review summarizes current approaches to overcome the immunosuppressive environment.
Simplified